4:31 PM ET
8-K
Business Update
Outlook Therapeutics Business Update
Outlook Therapeutics has established the wholesale acquisition cost (WAC) for LYTENAVA™ in the United States at $485 per vial. This pricing announcement follows the drug's regulatory progress and sets the commercial baseline for its market entry.